These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 36801818)
1. TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer. Xu S; Gao X; Qiu J; Hong F; Gao F; Wang X; Zhang S Aging (Albany NY); 2023 Feb; 15(4):1052-1073. PubMed ID: 36801818 [TBL] [Abstract][Full Text] [Related]
2. TIPE2 inhibits the migration and invasion of epithelial ovarian cancer cells by targeting Smad2 to reverse TGF-β1-induced EMT. Tang Z; Zhang D; Yao C; Jiang M; Wang C; Chen Z; Yu H; Xue C; Liu Y; Shi Y; Zhang L; Wang X; Wei Z FASEB J; 2024 Sep; 38(17):e70045. PubMed ID: 39259551 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo. Zeng S; Liu S; Feng J; Gao J; Xue F Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184 [TBL] [Abstract][Full Text] [Related]
4. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition. Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796 [TBL] [Abstract][Full Text] [Related]
5. TIPE2 suppresses the tumorigenesis, growth and metastasis of breast cancer via inhibition of the AKT and p38 signaling pathways. Zhang Z; Liu L; Liu C; Cao S; Zhu Y; Mei Q Oncol Rep; 2016 Dec; 36(6):3311-3316. PubMed ID: 27779698 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823 [TBL] [Abstract][Full Text] [Related]
7. TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway. Wang L; Chen C; Feng S; Tian J Mol Med Rep; 2018 May; 17(5):7017-7026. PubMed ID: 29568863 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway. Zhuang XH; Liu Y; Li JL Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31337688 [TBL] [Abstract][Full Text] [Related]
9. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis. Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282 [TBL] [Abstract][Full Text] [Related]
10. Circ-PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR-542-3p/CDC5L/PEAK1 pathway. Zhang C; Li Y; Zhao W; Liu G; Yang Q Cancer Med; 2020 May; 9(10):3500-3521. PubMed ID: 32167655 [TBL] [Abstract][Full Text] [Related]
11. TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway. Zhu L; Zhang X; Fu X; Li Z; Sun Z; Wu J; Wang X; Wang F; Li X; Niu S; Ding M; Yang Z; Yang W; Yin M; Zhang L; Zhang M J Transl Med; 2018 Jan; 16(1):7. PubMed ID: 29343267 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer. Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353 [TBL] [Abstract][Full Text] [Related]
13. TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway. Lu Q; Liu Z; Li Z; Chen J; Liao Z; Wu WR; Li YW Oncol Res; 2016; 24(5):305-313. PubMed ID: 27712587 [TBL] [Abstract][Full Text] [Related]
14. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer. Xu JH; Wang Y; Xu D Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074 [TBL] [Abstract][Full Text] [Related]
15. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer. Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423 [TBL] [Abstract][Full Text] [Related]
16. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment. Mao TL; Fan MH; Dlamini N; Liu CL Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541 [TBL] [Abstract][Full Text] [Related]
17. TIPE2 inhibits GC via regulation of cell proliferation, apoptosis and inflammation. Lin Z; Liu W; Xiao C; Fan Y; Zhuang G; Qi Z Oncol Rep; 2018 Sep; 40(3):1307-1316. PubMed ID: 30015980 [TBL] [Abstract][Full Text] [Related]
18. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression. Yao N; Sun JQ; Yu L; Ma L; Guo BQ Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289 [TBL] [Abstract][Full Text] [Related]
19. TIPE2 functions as a metastasis suppressor via negatively regulating β-catenin through activating GSK3β in gastric cancer. Wu J; Zhang H; Xu C; Xu H; Zhou X; Xie Y; Tao M Int J Oncol; 2016 Jan; 48(1):199-206. PubMed ID: 26530498 [TBL] [Abstract][Full Text] [Related]
20. TIPE2, a negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling. Peng Y; Zhao Q; Zhang H; Han B; Liu S; Han M; Liu S Oncol Rep; 2016 Apr; 35(4):2480-6. PubMed ID: 26781452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]